Isocorydine derivatives and their anticancer activities

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Isocorydine (ICD) is an alkaloid with potential anticancer properties.
• Structural modifications are explored to improve ICD's efficacy.
• Developing novel anticancer agents is a critical area of research.

Purpose of the Study:

• To synthesize and evaluate novel isocorydine derivatives for improved anticancer activity.
• To investigate the in vitro and in vivo anticancer effects of modified isocorydine compounds.
• To identify promising isocorydine-based lead compounds for drug development.

Main Methods:

• Chemical synthesis of ten isocorydine derivatives.
• In vitro evaluation of cytotoxicity against human lung, gastric, and liver cancer cell lines.
• In vivo assessment of tumor inhibition in murine sarcoma and hepatoma models.

Main Results:

• 8-Amino-isocorydine (8) and 6a,7-dihydrogen-isocorydione (10) inhibited growth of A549, SGC7901, and HepG2 cancer cell lines.
• Isocorydione (2) demonstrated tumor growth inhibition in S180-bearing mice.
• 8-Acetamino-isocorydine (11) showed efficacy against H22-induced tumors in mice.

Conclusions:

• Structural modifications of isocorydine at the C-8 position significantly enhance its biological activity.
• Isocorydine derivatives exhibit potent in vitro and in vivo anticancer effects.
• Isocorydine is a suitable lead compound for developing effective anticancer agents.